Singapore Approves Emergent BioSolutions' ACAM2000 Vaccine for Mpox Prevention
EBS sits 70% above its 52-week low of $4.71.
Summary
Emergent BioSolutions has secured approval from Singapore's Health Sciences Authority (HSA) for an expanded indication of its ACAM2000 vaccine, now including the prevention of mpox disease in high-risk adults. This regulatory milestone broadens the authorized use of ACAM2000 in Singapore, enhancing the company's role in public health preparedness. The approval is a positive development for Emergent BioSolutions, expanding the market and utility of one of its key medical countermeasures. This news follows a period of significant corporate activity for EBS, including debt refinancing and new manufacturing partnerships. Investors will monitor for further international approvals or procurement contracts related to this expanded indication.
At the time of this announcement, EBS was trading at $8.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $412.6M. The 52-week trading range was $4.71 to $14.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.